Selective targeting of melanoma and APCs using a recombinant antibody with TCR-like specificity directed toward a melanoma differentiation antigen

Journal of Immunology

Volumn 171, Issue 5, 2003, Pages 2197-2207

  Denkberg, Galit ^a   Lev, Avital ^a   Eisenbach, Lea ^c   Benhar, Itai ^b   Reiter, Yoram ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GLYCOPROTEIN GP 100; HLA A2 ANTIGEN; HYBRID PROTEIN; RECOMBINANT ANTIBODY; T LYMPHOCYTE RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ARTICLE; CANCER CELL DESTRUCTION; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; MELANOMA CELL; MOUSE; NONHUMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TARGET CELL; TARGET CELL DESTRUCTION; TRANSGENIC MOUSE;

EID: 0041428152     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.171.5.2197     Document Type: Article

References (40)

1. Boon, T., and P. van der Bruggen. 1996. Human tumor antigens recognized by T lymphocytes. J. Exp. Med. 183:725.
2. Rosenberg, S. A. 2001. Progress in human tumor immunology and immunotherapy. Nature 411:380.
3. Renkvist, N., C. Castelli, P. F. Robbins, and G. Parmiani. 2001. A listing of human tumor antigens recognized by T cells. Cancer Immunol. Immunother. 50:3.
4. Anichini, A., C. Maccalli, R. Mortarini, S. Salvi, A. Mazzocchi, P. Squarcina, M. Herlyn, and G. Parmiani. 1993. Melanoma cells and normal melanocytes share antigens recognized by HLA-A2-restricted cytotoxic T cell clones from melanoma patients. J. Exp. Med. 177:989.
5. Coulie, P. G., V. Brichard, A. Van Pel, T. Wolfel, J. Schneider, C. Traversari, S. Mattei, E. De Plaen, C. Lurquin, J. P. Szikora, et al. 1994. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 180:35.
6. Rivoltini, L., D. J. Loftus, P. Squarcina, C. Castelli, F. Rini, F. Arienti, F. Belli, F. M. Marincola, C. Geisler, A. Borsatti, et al. 1998. Recognition of melanoma-derived antigens by CTL: possible mechanisms involved in down-regulating anti-tumor T cell reactivity. Crit. Rev. Immunol. 18:55.
7. Offringa, R., S. H. van der Burg, F. Ossendorp, R. E. Toes, and C. J. Melief. 2000. Recognition of melanoma-derived antigens by CTL: possible mechanisms involved in down-regulating anti-tumor T-cell reactivity. Curr. Opin. Immunol. 12:576.
8. Restifo, N. P., F. Esquivel, Y. Kawakami, J. W. Yewdell, J. J. Mule, S. A. Rosenberg, and J. R. Bennink. 1993. Identification of human cancers deficient in antigen processing. J. Exp. Med. 177:265.
9. Seliger, B., M. J. Maeurer, and S. Ferrone. 2000. Antigen-processing machinery breakdown and tumor growth. Immunol. Today 21:455.
10. Esche, C., M. R. Shurin, and M. T. Lotze. 1999. The use of dendritic cells for cancer vaccination. Curr. Opin. Mol. Ther. 1:72.
11. Kugler, A., G. Stuhler, P. Walden, G. Zoller, A. Zobywalski, P. Brossart, U. Trefzer, S. Ullrich, C. A. Muller, V. Becker, et al. 2000. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat. Med. 6:332.
12. Pastan, I., and R. J. Kreitman. 2002. Immunotoxins in cancer therapy. Curr. Opin. Investig. Drugs 3:1089.
13. Porgador, A., J. W. Yewdell, Y. Deng, J. R. Bennink, and R. N. Germain. 1997. Localization, quantitation, and in situ detection of specific peptide-MHC class I complexes using a monoclonal antibody. Immunity 6:715.
14. Dadaglio, G., C. A. Nelson, M. B. Deck, S. J. Petzold, and E. R. Unanue. 1997. Characterization and quantitation of peptide-MHC complexes produced from hen egg lysozyme using a monoclonal antibody. Immunity 6:727.
15. Aharoni, R., D. Teitelbaum, R. Arnon, and J. Puri. 1991. Immunomodulation of experimental allergic encephalomyelitis by antibodies to the antigen-Ia complex. Nature 351:147.
16. Krogsgaard, M., K. W. Wucherpfennig, B. Canella, B. E. Hansen, A. Svejgaard, J. Pyrdol, H. Ditzel, C. Raine, J. Engberg, and L. Fugger. 2000. Visualization of myelin basic protein (MBP) T cell epitopes in multiple sclerosis lesions using a monoclonal antibody specific for the human histocompatibility leukocyte antigen (HLA)-DR2-MBP 85-99 complex. J. Exp. Med. 191:1395.
17. Andersen, P. S., A. Stryhn, B. E. Hansen, L. Fugger, J. Engberg, and S. Buus. 1996. A recombinant antibody with the antigen-specific, major histocompatibility complex-restricted specificity of T cells. Proc. Natl. Acad. Sci. USA 93:1820.
18. Chames, P., S. E. Hufton, P. G. Coulie, B. Uchanska-Ziegler, and H. R. Hoogenboom. 2000. Direct selection of a human antibody fragment directed against the tumor T-cell epitope HLA-A1-MAGE-A1 from a nonimmunized phage-Fab library. Proc. Natl. Acad. Sci. USA 97:7969.
19. Kawakami, Y., S. Eliyahu, C. H. Delgado, P. F. Robbins, K. Sakaguchi, E. Appella, J. R. Yannelli, G. J. Adema, T. Miki, and S. A. Rosenberg. 1994. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc. Natl. Acad. Sci. USA 91:6458.
20. Bakker, A. B., M. W. Schreurs, A. J. de Boer, Y. Kawakami, S. A. Rosenberg, G. J. Adema, and C. G. Figdor. 1994. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J. Exp. Med. 179:1005.
21. Kawakami, Y., S. Eliyahu, C. Jennings, K. Sakaguchi, X. Kang, S. Southwood, P. F. Robbins, A. Sette, E. Appella, and S. A. Rosenberg. 1995. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J. Immunol. 154:3961.
22. Cox, A. L., J. Skipper, Y. Chen, R. A. Henderson, T. L. Darrow, J. Shabanowitz, V. H. Engelhard, D. F. Hunt, and C. L. Slingluff, Jr. 1994. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 264:716.
23. Denkberg, G., C. J. Cohen, D. Segal, A. F. Kirkin, and Y. Reiter. 2000. Recombinant human single-chain MHC-peptide complexes made from E. coli by in vitro refolding: functional single-chain MHC-peptide complexes and tetramers with tumor associated antigens. Eur. J. Immunol. 30:3522.
24. Denkberg, G., C. J. Cohen, and Y. Reiter. 2001. Critical role for CD8 in binding of MHC tetramers to TCR: CD8 antibodies block specific binding of human tumor-specific MHC-peptide tetramers to TCR. J. Immunol. 167:270.
25. Altman, J. D., P. A. Moss, P. J. Goulder, D. H. Barouch, M. G. McHeyzer-Williams, J. I. Bell, A. J. McMichael, and M. M. Davis. 1996. Phenotypic analysis of antigen-specific T lymphocytes. [Published erratum appears in 1998 Science 280:1821.] Science 274, 94.
26. 2m double knockout mice. J. Exp. Med. 185:2043.
27. Benhar, I, and Y. Reiter. 2002. Phage display of antibody scFv fragments. Curr. Protocols Immunol. 48:59.
28. Berdichevsky, Y., E. Ben-Zeev, R. Lamed, and I. Benhar. 1999. Phage display of a cellulose binding domain from Clostridium thermocellum and its application as a tool for antibody engineering. J. Immunol. Methods 228:151.
29. De Haard, H. J., N. van Neer, A. Reurs, S. E. Hufton, R. C. Roovers, P. Henderikx, A. P. de Bruine, J. W. Arends, and H. R. Hoogenboom. 1999. A large non-immunized human Fab fragment phage library that permits rapid isolation and kinetic analysis of high affinity antibodies. J. Biol. Chem. 274:18218.
30. Brinkmann, U., L. H. Pai, D. J. FitzGerald, M. Willingham, and I. Pastan. 1991. B3(Fv)-PE38 KDEL, a single-chain immunotoxin that causes complete regression of human carcinoma in mice. Proc. Natl. Acad. Sci. USA 88:8616.
31. Parkhurst, M. R., M. L. Salgaller, S. Southwood, P. F. Robbins, A. Sette, S. A. Rosenberg, and Y. Kawakami. 1996. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J. Immunol. 157:2539.
32. Vonderheide, R. H., W. C. Hahn, J. L. Schultze, and L. M. Nadler. 1999. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 10:673.
33. 2 microglobulin single chain. Int. J. Cancer 85:391.
34. + T cells with soluble HLA-A2/Tax11-19 tetramer complexes in patients with human T cell lymphotropic virus-associated myelopathy. J. Immunol. 162:1765.
35. Lee, P. P., C. Yee, P. A. Savage, L. Fong, D. Brockstedt, J. S. Weber, D. Johnson, S. Swetter, J. Thompson, P. D. Greenberg, et al. 1999. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat. Med. 5:677.
36. Ogg, G. S., X. Jin, S. Bonhoeffer, P. R. Dunbar, M. A. Nowak, S. Monard, J. P. Segal, Y. Cao, S. L. Rowland-Jones, V. Cerundolo, et al. 1998. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science 279:2103.
37. Lode, H. N., and R. A. Reisfeld. 2000. Targeted cytokines for cancer immunotherapy. Immunol. Res. 21:279.
38. Withoff, S., W. Helfrich, L. F. de Leij, and G. Molema. 2001. Bi-specific antibody therapy for the treatment of cancer. Curr. Opin. Mol. Ther. 3:53.
39. Reiter, Y., A. Di Carlo, L. Fugger, J. Engberg, and I. Pastan. 1997. Peptide-specific killing of antigen-presenting cells by a recombinant antibody-toxin fusion protein targeted to major histocompatibility complex/peptide class I complexes with T cell receptor-like specificity. Proc. Natl. Acad. Sci. USA 94:4631.
40. Chowdhury, P. S., and I. Pastan. 1999. Improving antibody affinity by mimicking somatic hypermutation in vitro. Nat. Biotechnol. 17:568.